Tags : Broaden

Strata Oncology Collaborates with Mirati Therapeutics to Broaden Enrollment in

Tuba Khan August 13, 2020

Shots: The multiple expansion cohort will assess the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors harboring a KRAS G12C mutation […]readmore

MedTech

Roche Collaborates with Illumina to Expand the Adoption of NGS

Tuba Khan January 14, 2020

Shots: Roche signs a 15yrs. non-exclusive agreement with Illumina, allowing patients to access next-generation sequencing (NGS) based testing in oncology Roche to get right to develop & commercialize AVENIO IVD […]readmore

Tags : Broaden

Strata Oncology Collaborates with Mirati Therapeutics to Broaden Enrollment in

Roche Collaborates with Illumina to Expand the Adoption of NGS

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Broaden

Strata Oncology Collaborates with Mirati Therapeutics to Broaden Enrollment in

Roche Collaborates with Illumina to Expand the Adoption of NGS

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company